Printer Friendly

Caladrius Biosciences signs material transfer agreement with University of Southern California and California Institute of Technology.

M2 EQUITYBITES-June 22, 2015-Caladrius Biosciences signs material transfer agreement with University of Southern California and California Institute of Technology

(C)2015 M2 COMMUNICATIONS http://www.m2.com

Caladrius Biosciences, a clinical-stage biopharmaceutical company that develops cell based therapeutics in the United States, has signed a material transfer agreement with the University of Southern California and the California Institute of Technology.

It was reported on Friday that the contract has been signed to explore next-generation strategies for the company's core cancer technology. The research collaboration will be based on the company's manufacturing protocol for its lead cancer program, CLBS20 (NBS20).

All the parties will find new techniques to further improve the isolation of cancer initiating cells, with the aim of increasing the number of cancer patients that are likely to benefit from treatment. Presently, the product is being assessed in a Phase III trial (Intus Study) for the treatment of late-stage melanoma.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 22, 2015
Words:162
Previous Article:EVA Hello Kitty Shining Star lands in Houston.
Next Article:Provectus Biopharmaceuticals anticipates USD13.1m in public offering.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters